We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Type 1 Diabetes Risk Reflected in Gut Microbiome

By LabMedica International staff writers
Posted on 06 Sep 2019
Type 1 diabetes mellitus (T1D) is an autoimmune disorder characterized by the destruction of insulin-producing ß-cells in the pancreas, resulting in a life-long dependence on exogenous insulin. More...
T1D is an autoimmune condition that can develop at any age.

According to recent estimates, there are 1.3 million adults in the USA living with diabetes. Although the causes of type 1 diabetes are not yet known, there are many risk factors for this metabolic condition. Genetic risk factors for T1D have been identified in over 50 diverse genetic loci, but the greatest genetic determinant of T1D remains the human leukocyte antigen (HLA) region.

A team of scientists including those from Linköping University (Linköping, Sweden) examined data available from the All Babies in Southeast Sweden (ABIS) study. They conducted the ABIS study with the aim of understanding why children develop conditions that primarily involve the immune system. The ABIS study contains data from questionnaires and biological samples on over 17,000 children born in 1997–1999. As part of the study, scientists collected biological samples "at birth, 1 year, 2–3 years, and 5–6 years of age." The samples included "blood, urine, stool, and hair."

To enable the comparison of different levels of HLA risk for developing T1D autoimmunity, subjects with available HLA genotype data were placed into one of four categories of risk based on their HLA genotype. DNA from each sample was extracted from ~200 mg of stool, using the E.Z.N.A Stool Extraction Kit. DNA used for subsequent polymerase chain reaction (PCR) was quantified and assessed for purity using a NanoDrop spectrophotometer. Amplicons from each sample were pooled and sequenced on the MiSeq platform.

The scientists reported that both the core microbiome and beta diversity differ with HLA risk group and genotype. In addition, protective HLA haplotypes are associated with bacterial genera Intestinibacter and Romboutsia. They found that children with a high genetic risk had a different composition in their gut microbiota and different gut microbiomes than children with a low risk. The authors concluded that the information gained from this type of cohort furthers our understanding of how HLA genetic risk drives changes in the gut microbiome and how genetics may be “setting the stage” for environmental triggers that ultimately lead to T1D autoimmunity. The study was published on August 9, 2019, in the journal Nature Communications.

Related Links:
Linköping University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.